Impact of the Coronavirus Disease 2019 (COVID-19) on Sperm Parameters (NCT04937608) | Clinical Trial Compass
TerminatedNot Applicable
Impact of the Coronavirus Disease 2019 (COVID-19) on Sperm Parameters
Stopped: Lack of staff
Canada2 participantsStarted 2021-08-13
Plain-language summary
This study aims to better understand the effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, virus that causes the coronavirus disease 2019 (COVID-19), on male fertility.
Who can participate
Age range18 Years – 45 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* All men aged 18 to 45 having a sperm analysis done at the Fertilys fertility center in the last 2 years who have not contracted COVID-19, agreeing to participate in the study and having signed the consent form to participate in the study.
* All men aged 18 to 45 having a sperm analysis done at the Fertilys fertility center in the last 2 years) who have contracted COVID-19 within the last 6 months, agreeing to participating in the study and having signed the consent form to participate in the study.
* All men aged 18 to 45 years with a sperm concentration ≥ 15 million/mL, progressive motility ≥ 20% and a percentage of normal forms ≥ 2%.
Exclusion Criteria:
* Men aged under 18 and over 45.
* Men who cannot produce a sperm sample by antegrade ejaculation.
* Men whose sperm concentration is \<15 million/mL, progressive motility \<20% and a percentage of normal forms \<2%, determined following the production of a "reference" sperm sample, carried out before March 2020, i.e. before the COVID-19 pandemic.
What they're measuring
1
Changes in sperm parameters quality
Timeframe: Pre-infection, on the day of recruitment and six month later
2
Viral RNA in seminal plasma
Timeframe: Pre-infection, on the day of recruitment and six month later